Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)
HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $8 Price Target
CARISMA Therapeutics Analyst Ratings
CARISMA Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $8 Price Target
Buy Rating Affirmed for Carisma Therapeutics Amid Progress in CAR-Monocyte Cancer Therapy
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
CARISMA Therapeutics Analyst Ratings
Buy Rating Affirmed for Carisma Therapeutics Amid Promising Cancer Treatment Developments
Buy Rating for Carisma Therapeutics: Innovative CAR-M Therapies Poised for Market Growth
Buy Rating on Carisma Therapeutics: Pioneering CAR-M Therapies in Oncology and Fibrosis
Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Carisma Therapeutics (CARM)
Buy Rating Affirmed: Promising Clinical Data and Strategic Shift Bolster Carisma Therapeutics' Outlook
Promising Future for Carisma Therapeutics' Cancer Immunotherapy: A Buy Rating Analysis
CARISMA THERAPEUTICS (CARM.US) was first covered by BTIG and given a buy rating, with a target price of $6.00.
CARISMA Therapeutics Analyst Ratings
BTIG Initiates Coverage On CARISMA Therapeutics With Buy Rating, Announces Price Target of $6
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)
No Data